Table 2.
Variable (Mean ± SD) |
Group | 1st Assessment (time 0) | 2nd Assessment (time 1) |
3rd Assessment (time 2) |
---|---|---|---|---|
HDRS | ||||
Controls | 38.7 ± 7.6 | 15.9 ± 8.6+ | 8.1 ± 6.6∞ | |
Topiramate | 39.6 ± 5.5 | 12.5 ± 3.1*+ | 4.9 ± 3.1*∞ | |
HARS | ||||
Controls | 30.5 ± 10.2 | 13.9 ± 6.7+ | 7.1 ± 6.2∞ | |
Topiramate | 31.8 ± 5.3 | 10.9 ± 3.6*+ | 4.3 ± 3.8*∞ | |
GAS | ||||
Controls | 46.7 ± 5.1 | 75.6 ± 9.3+ | 85.4 ± 8.5∞ | |
Topiramate | 46.6 ± 4.7 | 74.3 ± 6.7+ | 84.3 ± 5.6∞ | |
OCDS | ||||
Controls | 37.2 ± 8.3 | 17.3 ± 3.9+ | 13.3 ± 2.8∞ | |
Topiramate | 37.6 ± 7.8 | 15.3 ± 3.9*+ | 10.3 ± 3.1**∞ |
Statistics: Between groups (independent samples t-test); within groups (RMANOVA)
*Significant difference between controls and topiramate augmentation group (< 0.05)
** Significant difference between controls and topiramate augmentation group (< 0.01)
+ Significant difference between 2nd and 1st assessment (< 0.01)
∞ Significant difference between 3rd and 2nd assessment (< 0.01)